As of Nov 19, 2026, 2 of 2 active firms rate ANTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ANTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.21 – $-0.21 · 1 analysts · -28% YoY
Next period, 1 analysts expect AN2 Therapeutics Inc to earn $-0.21 a share (range $-0.21 – $-0.21), versus $-0.29 a year earlier. Full-year consensus is $-0.85, growing to $-0.77 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering AN2 Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANTX.
#1
Roy Buchanan
JMP Securities · Rank #176
Buy
$2.00-59.4% to target
Overall win rate
47%
+ Follow
#2
Joseph Schwartz
Leerink Partners · Rank #242
Buy
$9.00+82.6% to target
Overall win rate
36%
+ Follow
#3
Liisa Bayko
Evercore ISI Group
Sell
$2.00-59.4% to target
Coverage
—
+ Follow
#4
BC
Brad Canino
Guggenheim
Buy
$9.00+82.6% to target
Coverage
—
+ Follow
#5
Bradley Canino
Guggenheim
Buy
$9.00+82.6% to target
Coverage
—
+ Follow
ANTX stock forecast FAQ
What is ANTX's average 12-month price target?+
The 2 active firms with a live target average $9.00 for AN2 Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $9.00 low, as of Nov 19, 2026.
Is ANTX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ANTX?+
2 active firms have a recognized rating on AN2 Therapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ANTX?+
Among analysts who currently cover ANTX, Roy Buchanan of JMP Securities has the strongest overall Quantellect track record (Rank #176). Their current call is Buy with a $2.00 target.
What is AN2 Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.21 – $-0.21) across 1 analysts. Full-year EPS is projected at $-0.85, rising to $-0.77 the following year.
How much revenue is AN2 Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ANTX lately?+
As of Nov 19, 2026, 2 of 2 active firms rate ANTX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.